Evidence map›Paper›PMID 40277768›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Long-Term Patient-Reported Bowel and Urinary Quality of Life in Patients Treated with Intensity-Modulated Radiotherapy Versus Intensity-Modulated Proton Therapy for Localized Prostate Cancer.

Kimberly R Gergelis, Miao Bai, Jiasen Ma, David M Routman, Bradley J Stish, Brian J Davis, Thomas M Pisansky, Thomas J Whitaker, Richard Choo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kimberly R GergelisDepartment of Radiation Oncology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY 14642, USA.ORCID 0000-0002-8130-8327
Miao BaiDepartment of Operations and Information Management, University of Connecticut, 352 Mansfield Rd, Storrs, CT 06269, USA.ORCID 0000-0003-3786-5326
Jiasen MaDepartment of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
David M RoutmanDepartment of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Bradley J StishDepartment of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Brian J DavisDepartment of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.ORCID 0000-0002-8288-1096
Thomas M PisanskyDepartment of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.ORCID 0009-0009-4875-2061
Thomas J WhitakerDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Richard ChooDepartment of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to compare long-term patient-reported outcomes in bowel and urinary domains between intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) for localized prostate cancer. METHODS AND MATERIALS: Patients with clinical T1-T2 prostate cancer receiving IMRT or IMPT at a tertiary cancer center from 2015-2018 were analyzed to determine the changes in the prospectively collected bowel function (BF), urinary irritative/obstructive symptoms (UO), and urinary incontinence (UI) domains of EPIC-26. The mean changes in EPIC-26 scores were evaluated from pretreatment to 24 months post-radiotherapy for each modality. A score change >50% of the baseline standard deviation was considered a clinically meaningful change.

resultsA total of 82 patients treated with IMRT (52.2%) and 56 patients treated with IMPT (53.3%) completed the questionnaire at baseline and 24 months post-RT. There were no baseline differences in domain scores between treatment modalities. At 24 months post-radiotherapy, there was a significant and clinically meaningful decline in the BF mean score in the IMRT cohort (-4.52 (range -50, 29.17),

conclusionsIMPT leads to a smaller decrease in BF than IMRT at 24 months post-RT, while there was no differential effect on UO and UI.

Indexed as

Prostatic NeoplasmsProton TherapyQuality of LifeRadiotherapy, Intensity-ModulatedAgedAged, 80 and overHumansMaleMiddle AgedPatient Reported Outcome MeasuresEPIC-26intensity-modulated proton therapyintensity-modulated radiotherapyprostate cancerquality of life

Identifiers

PMID40277768
PMCPMC12025910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.